OncLive TV

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the importance of the phase III ECHELON-2 data in peripheral T-cell lymphoma (PTCL).

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, previews discussion topics for the upcoming webinar hosted by OncLive on the novel coronavirus 2019 (COVID-19).

Benjamin P. Levy, MD, discusses emerging biomarkers and their respective therapies in lung cancer.

Robb S. Friedman, MD, discusses the mechanism of action of selinexor in multiple myeloma.

Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.

Tannaz Armaghany, MD, discusses sorafenib versus lenvatinib as first-line therapy for patients with hepatocellular carcinoma.

Diane M. Simeone, MD, explains which patients with pancreatic cancer should receive neoadjuvant therapy.

Bruce G. Raphael, MD, discusses the risk of tumor lysis syndrome in chronic lymphocytic leukemia.

Michael Choi, MD, discusses the utility of duvelisib in chronic lymphocytic leukemia.

Shubham Pant, MD, discusses choosing therapy for the frontline and beyond in pancreatic cancer.

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the potential impact of targeted therapy approvals on the use of genetic testing in prostate cancer.

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the use of pathologic complete response (pCR) rate as a surrogate marker for event-free survival (EFS) in triple-negative breast cancer (TNBC).

Tania Jain, MBBS, discusses treatment options for patients with myelofibrosis who progress following allogeneic stem cell transplant.

Marc J. Braunstein, MD, PhD, discusses transplant eligibility in multiple myeloma.

Gopa Iyer, MD, discusses the challenges faced with identifying an optimal screening methodology to select patients with bladder cancer for FGFR inhibitor therapy.

Reza Mehrazin, MD, discusses the findings of the phase III CARMENA trial in metastatic renal-cell carcinoma.

Kathleen Moore, MD, discusses the early phase data that led to the development of the phase III FORWARD I/ GOG 3011 trial in ovarian cancer.

Michael Choi, MD, discusses how up-front treatment decisions impact what options can be given in the relapsed/refractory setting for patients with chronic lymphocytic leukemia.

Nancy U. Lin, MD, discusses central nervous system activity with HER2-directed TKIs in HER2-positive breast cancer.

David Miklos, MD, discusses the safety profile of KTE-X19 in mantle cell lymphoma.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

Filipa Lynce, MD, discusses remaining questions regarding the use of PARP inhibitors in breast cancer.

OncLive interviewed experts at the State of the Science Summits™ in March 2020 on the impact of the COVID-19 pandemic on cancer care and shared what advice they have been giving their patients.

Farrukh Awan, MD, discusses novel approaches under investigation in relapsed/refractory chronic lymphocytic leukemia.

Erin M. Bertino, MD, discusses the use of dacomitinib (Vizimpro) in the treatment of patients with non–small cell lung cancer with EGFR mutations and its place among other available EGFR TKIs.

Jubilee Brown, MD, discusses germline and somatic testing in ovarian cancer.

Ziad Bakouny, MD, MSc, discusses the utility of checkpoint inhibitors in renal cell carcinoma with sarcomatoid differentiation.

Ahmed O. Kaseb, MD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses research with targeted therapy in hepatocellular carcinoma (HCC).